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Abstract
miRNAs were recently implicated in the pathogenesis of numerous diseases, including neurological disorders such as
Parkinson’s disease (PD). miRNAs are abundant in the nervous system, essential for efficient brain function and play important
rolesinneuronalpatterningand cell specification.Tofurtherinvestigate theirinvolvementinthe etiologyofPD,weconducted
miRNA expression profiling in peripheral blood mononuclear cells (PBMCs) of 19 patients and 13 controls using microarrays.
We found 18 miRNAs differentially expressed, and pathway analysis of 662 predicted target genes of 11 of these miRNAs
revealed an over-representation in pathways previously linked to PD as well as novel pathways. To narrow down the genes for
furtherinvestigations,weundertook aparallelapproachusingchromatin immunoprecipitation-sequencing(ChIP-seq)analysis
to uncover genome-wide interactions of a-synuclein, a molecule with a central role in both monogenic and idiopathic PD.
Convergence of ChIP-seq and miRNomics data highlighted the glycosphingolipid biosynthesis and the ubiquitin proteasome
system as key players in PD. We then tested the association of target genes belonging to these pathways with PD risk, and
identified nine SNPs in USP37 consistently associated with PD susceptibility in three genome-wide association studies (GWAS)
datasets (0.46#OR#0.63) and highly significant in the meta-dataset (3.36610
24,p,1.94610
23). A SNP in ST8SIA4 was also
highly associated with PD (p=6.15610
23) in the meta-dataset. These findings suggest that several miRNAs may act as
regulators of both known and novel biological processes leading to idiopathic PD.
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Introduction
Parkinson’s disease is a neurodegenerative disorder clinically
characterized by bradykinesia, muscle rigidity, resting tremor and,
in more advanced stages, postural instability. Its main pathological
hallmark is the loss of over 70% of the dopaminergic neurons
(DNs) within the substantia nigra (SN), leading to functional deficits
in the basal ganglia circuitry due to reduced levels of dopamine.
The identification of several genes causing monogenic forms of PD
(e.g. a-synuclein [SNCA], Parkin, DJ-1, PINK1, LRRK2) has led to the
generalized view that protein misfolding, mitochondrial dysfunc-
tion, impaired oxidative stress response, and altered function of the
ubiquitin-proteasome system are central pathogenic mechanisms
underlying the familial forms of PD [1]. However, far less is known
about the molecular mechanisms underlying idiopathic PD.
miRNAs have recently emerged as an important class of small
RNAs (,22 nucleotides) that act as post-transcriptional regulators
of gene expression by base-pairing with their target mRNAs. They
regulate neuronal processes such as brain morphogenesis, neuronal
cell fate and differentiation, and transcription of neuronal-specific
genes [2]. Recent studies have linked several miRNAs to sporadic
PD. miR-133b was found to be specifically enriched in midbrain
DNs of normal individuals and reduced in PD patients [3]. In vitro,
miR-133b was found to regulate DN maturation and function
through a negative feedback loop with Pitx3, a transcription factor
that activates midbrain DN gene expression [3]. miR-433 binds to a
polymorphism in the promoter region of the fibroblast growth factor 20
gene (FGF20) which is associated with PD [4]. The risk allele
disrupts the binding site of miR-433, resulting in enhanced
translation of FGF20 and increased a-synuclein expression [4].
miR-7 and miR-153 were shown to be predominantly expressed in
the brain and to regulate a-synuclein expression levels [5–6]. In
addition, mutant LRRK2 was found to negatively regulate
translational repression mediated by miRNAs [7]. None of these
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blood of PD patients. Since previous studies were restricted to brain
tissue and limited in the number of samples and miRNAs evaluated,
we sought to investigate the role of miRNAs in idiopathic PD by
performing microarray expression profiling in blood samples of PD
patients and controls.
a-synuclein is a key player in PD. It is the main component of
the protein aggregates accumulated in the brain of patients, a
pathologic hallmark of this disease. Further support for the
implication of this molecule in PD has been gathered from GWAS
[8–13] where the genetic architecture of the most common forms of
PD has been investigated. Genome-wide significance has been
reached in three of these GWAS [11–13], and SNCA and the MAPT
region have been confirmed as major PD risk loci. In addition,
mutations (e.g. A53T, A30P, E46K, and gene duplications and
triplications) and polymorphisms in SNCA are linked both to
monogenic and complex forms of PD, respectively [14]. Despite its
recognized importance,themolecular mechanismsunderpinningits
role in PD are not yet clear. Although pathways like the ubiquitin
proteasome system and chaperone-mediated autophagy have been
implicated in a-synuclein turnover, our knowledge of its biology is
still limited [15]. Here, we used ChIP-seq as an unbiased approach
to identify a-synuclein binding sites genome-wide. This technology
captures the full spectrum of actions of this molecule across the
genome, providing information that will not only provide insights
intothe putative roles of a-synucleinin the nucleus, butalso connect
it to previously unanticipated cellular processes.
miRNAs have been studied for their direct or indirect action on
a-synuclein [4–6] but they are predicted to target a wide range of
genes. Given the centrality of a-synuclein in PD, here we propose
to go one step further and not only to look at its interactions with
other molecules and pathways but also to look into the cross-talk
between the a-synuclein interactome and miRNAs.
To identify novel genes and pathways associated with PD, we
followed an integrative approach, intersecting the results from
these complementary genome-wide analyses to further test them in
a GWAS meta-dataset, gaining further insight into the molecular
mechanisms involved. Importantly, a PD miRNA signature with
18 miRNAs was obtained and two pathways (the glycosphingolipid
biosynthesis - ganglioseries and the protein ubiquitination path-
way) were highlighted as key players in PD pathogenesis. Further-
more, 3 miRNAs emerged as main modulators of these two pathways
(miR-30b, miR-30c and miR-26a), and two genes (USP37 and
ST8SIA4) were found significantly associated with PD susceptibility.
Results
miRNA expression profiling
The principal demographic and clinical characteristics of the
nineteen unrelated idiopathic PD patients and thirteen controls
included in the miRNA profiling study are summarized in Table 1.
Recruited patients covered the full spectrum of early to advanced
PD (Hoehn & Yahr stage 1 to 5) and age was comparable across
the two groups (average age-at-examination 6 SD of 65.164.4
years in patients and 64.465.9 years in controls).
We conducted miRNA expression profiling in PBMCs of the
study participants using Exiqon-developed miRCURY
TM LNA
microarrays spotted with four replicate probes for 763 human
miRNAs (733 from miRBase (http://www.mirbase.org/) database
release 13 plus 30 miRPlus novel human miRNAs from Exiqon).
We found that 490 of these miRNAs were expressed in our
samples. Differentially expressed miRNAs were identified using a
linear modelling approach for each miRNA to estimate the fold-
changes and standard errors, followed by an empirical Bayes
smoothing to moderate the standard errors [16]. Empirical
Bayesian methods provide more stable results even when the
number of arrays is small. Taking a B-statistic (logarithm of the
posterior odds that a gene is differentially expressed) threshold of
1, eighteen miRNAs were found differentially expressed (Table 2).
Interestingly, all of these miRNAs are under-expressed in PD
samples (fold-changes ranging from 21.41 to 23.02). To globally
validate the microarray results, we performed qRT-PCR for five
miRNAs, three of which had negative fold-changes (miR-126*,
miR-32, and miR-101), and two had positive fold-changes (miR-
15b and miR-550) in PD cases. Only miR-126* was significantly
under-expressed in our microarray experiment (B$1), while the
other four miRNAs tested had B-statistics below 1. qRT-PCR
supported our microarray findings (Figure S1) in terms of
directionality (positive versus negative fold-changes) and strength
of significance of differential expression (the lowest p-value in the
qRT-PCR experiment was obtained for miR-126* which was the
only miRNA among those five with a B-statistic greater than 1).
Unsupervised hierarchical clustering (HC) of the samples using
the 18 differentially expressed miRNAs reveals that PD cases and
controls cluster into separate groups with the exception of controls
C2, C3, C7, and C13 and cases P18 and P19 (Figure 1). A similar
pattern is observed using the principal component analysis (PCA)
(Figure S2), where the first principal component explains 84.1% of
the variance and allows a clear separation of most samples
according to affection status. Supporting the consistency of our
results, analysis of variance revealed that the main source of
variation in the expression data is the individual’s affection status
(Figure S3), and we typically observed similar expression patterns
for miRNAs derived from the same stem-loop precursor (e.g. co-
clustering in Figure 1 of miR-199a-5p and miR-199a-3p, and of
miR-151-5p and miR-151-3p, which derive from the miR-199a
and miR-151 stem-loop precursors, respectively).
Predicted target genes and pathway analysis
In an effort to place these miRNA expression profiling findings
into a biological context and to generate new testable hypotheses,
and given that miRNAs have very few experimentally validated
targets, we first performed an in silico search for predicted target
genes of the 18 differentially expressed miRNAs. In view of the
fact that no particular target prediction software has consistently
shown to be superior to all others, we used the ‘‘Predicted
Targets’’ tool in the miRecords resource [17] which integrates the
results of eleven established miRNA target prediction algorithms.
Six softwares (miRanda v.1.9 [18], MirTarget2 v.2.0 [19], PicTar
[20], PITA v.6 [21], RNAhybrid v.2.2 [22], and TargetScan v.4.1
[23]) generated almost all (.95%) of the predicted target genes for
the miRNAs of interest. These six softwares rely on very distinct
principles and methods, namely near-perfect base complementar-
ity in the ‘‘seed’’ region, evolutionary interspecies conservation,
miRNA-mRNA duplex thermodynamic stability, target site
accessibility, and machine learning techniques. Given that these
predictions have not been experimentally validated, we opted for a
stringent threshold of at least six softwares to select the predicted
miRNA target genes for follow-up. In this case, seven miRNAs
(miR-374a, miR-199a-3p/miR-199b-3p, miR-126*, miR-151-5p,
miR-126, miR-147, and miR-374b) had no predicted target genes,
and the remaining eleven miRNAs were predicted to target 662
unique genes (Table S1).
To correlate expression findings with relevant biological
processes and pathways, we performed pathway analysis using
the manually-curated literature-based Ingenuity Pathway Analysis
(IPA) database. Among the 662 unique predicted target genes used
to query the database, 553 were eligible for functions/pathway/list
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our target genes were (Figure S4A and Table S2): glycosphingo-
lipid biosynthesis - neolactoseries (5 molecules), semaphorin
signaling in neurons (7 molecules), DNA methylation and
transcriptional repression signaling (4 molecules), retinoic acid
receptor (RAR) activation (13 molecules), hypoxia signaling in the
cardiovascular system (8 molecules), glycosphingolipid biosynthesis
- ganglioseries (4 molecules), O-glycan biosynthesis (4 molecules),
protein ubiquination pathway (16 molecules), synaptic long-term
potentiation (9 molecules), and nicotinate and nicotinamide
metabolism (8 molecules).
a-synuclein target genes
High-throughput microarray studies typically generate too
many leads to follow-up, requiring subsequent validation steps.
To narrow down the genes for further investigation in association
studies, we intersected the results from the miRNA pathway
analysis with those from a study aimed at unveiling genomic
targets for a-synuclein modulation (interacton), which may suggest
novel unanticipated pathogenic pathways in PD.
To identify a-synuclein binding sites throughout the genome,
we performed chromatin immunoprecipitation (ChIP) with an
anti-a-synuclein antibody in cultured human H4 neuroglioma cells
expressing endogenous levels of the protein. Next, high-through-
put sequencing of the co-immunoprecipitated genomic DNA
fragments was performed. Mapping the sequenced fragments to
the reference genome gives a profile of the DNA regions that are
enriched (‘‘peaks’’) in the pulldown, with a peak being defined as a
region that contains significantly more reads from an experimental
pulldown than from a negative control (ChIP sample and total
input, respectively). The analysis revealed 7666 statistically
significant peaks corresponding to 238 unique genes, ranging in
Table 1. Principal demographic and clinical characteristics of the miRNA profiling study participants.
ID
Affection
status Age Sex AAO
Years since
onset
Hoehn &
Yahr stage
Schwab &
England score
UPDRS III
score
UPDRS
I+II+III score
P1 PD 58 M 50 8 1 90% 6 12
P2 PD 60 M 57 2 2 100% 3 8
P3 PD 61 M 56 5 1.5 90% 10 15
P4 PD 62 M 55 7 2.5 70% 17 50
P5 PD 64 M 61 3 2.5 90% 20 28
P6 PD 65 M 63 2 2.5 90% 12 15
P7 PD 68 M 55 13 4 30% 41 58
P8 PD 70 M 50 20 2.5 80% 16 21
P9 PD 71 M 60 10 2.5 50% 52 87
P10 PD 71 M 61 11 2.5 80% 23 45
P11 PD 58 F 45 13 2.5 70% 38 63
P12 PD 61 F 50 11 2.5 60% 29 41
P13 PD 62 F 45 17 2.5 70% 35 70
P14 PD 64 F 60 4 2.5 90% 24 31
P15 PD 67 F 65 2 2.5 90% 20 26
P16 PD 68 F 60 8 2 80% 12 16
P17 PD 68 F 59 9 3 80% 24 29
P18 PD 69 F 56 13 2.5 40% 31 93
P19 PD 70 F 62 8 5 NA 71 106
C1 CTRL 63 M
C2 CTRL 64 M
C3 CTRL 66 M
C4 CTRL 71 M
C5 CTRL 73 M
C6 CTRL 51 F
C7 CTRL 57 F
C8 CTRL 60 F
C9 CTRL 63 F
C10 CTRL 66 F
C11 CTRL 66 F
C12 CTRL 67 F
C13 CTRL 70 F
PD: Parkinson’s Disease; CTRL: Control; M: Male; F: Female; AAO: Age-at-onset; NA: Not available; UPDRS III: Unified Parkinson’s disease rating scale Part III; UPDRS I+II+III:
Unified Parkinson’s disease rating scale Part I, Part II and Part III.
doi:10.1371/journal.pone.0025443.t001
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and specificity of the antibody were confirmed by ChIP analysis
using the CDC-42 promoter, previously reported as a putative
target of a-synuclein. Additionally, the promoter enrichment was
assayed using the NEDD4 promoter sequence, shown in our
analysis to significantly bind a-synuclein (NEDD4 belongs to the
ubiquitin proteasome pathway). Real-time PCR analysis of the
immunoprecipitated DNA resulted in a significant enrichment for
a-synuclein binding to both the CDC-42 and NEDD4 promoter,
when compared to the myoglobin exon 2 non-binding control
region (2.36- and 1.51-fold enrichment for CDC-42 and NEDD4,
respectively).
IPA analysis revealed that the top ten canonical pathways over-
represented among the 238 genes targeted by a-synuclein were
(Figure S4B): fatty acid biosynthesis (ACACB, OLAH), mechanisms
of viral exit from host cells (NEDD4, PRKCG, VPS24), aldosterone
signaling in epithelial cells (ACCN1, NEDD4, PIP5K1C, PRKCG),
PPAR signaling (IL1R2, INSR, MAP4K4, PDGFB), hepatic
cholestasis (ESR1, GCGR, IL1R2, INSR, PRKCG), protein ubiqui-
tination pathway (AMFR, NEDD4, PSMD1, UBR2, USP3, USP6),
rac signaling (ANK1, MCF2L, PAK3, PIP5K1C), clathrin-mediated
endocytosis signaling (AMPH, FGF12, FGF13, PDGFB, PIP5K1C),
glycosphingolipid biosynthesis - ganglioseries (ELOVL2, ST8SIA1),
and ephrin receptor signaling (EPHA6, MAP4K4, PAK3, PDGFB,
WIPF1).
We hypothesized that a-synuclein ChIP peaks/pathways
common to predicted target genes/pathways from our miRNA
analysis, particularly in the top ten pathways, would highlight
important genes and pathways implicated in PD pathology.
Glycosphingolipid biosynthesis - ganglioseries together with the
protein ubiquitination pathway emerged in both the miRNome
and the interacton IPA analyses, with three common genes, USP6,
NEDD4, and USP3, in the protein ubiquitination pathway. These
three genes are also putative targets of three miRNAs (miR-30b,
miR-30c, miR-26a) over-represented in the miRNomic pathway
analysis (Table S2).
Association study
Given that the convergence of the miRNomics and the a-
synuclein interacton approaches highlighted multiple genes in the
glycosphingolipid biosynthesis and the protein ubiquitination
pathways previously been linked to PD [24–27], we further
investigated the association of the genes in these pathways with risk
for PD. Six independent genome-wide association studies
investigated the genomic susceptibility to PD [8–13], and we
performed a joint analysis of the three datasets to which we had
access [9,10,13]. The meta-dataset in this study includes 1752 PD
cases and 1745 controls. We tested the association of 388 SNPs in
20 genes predicted to be targets of 11 out of the 18 differentially
expressed miRNAs belonging to the glycosphingolipid biosynthesis
- ganglioseries and the protein ubiquitination pathways (Table S4).
The number of polymorphisms tested in each gene and the
markers with positive association findings are summarized in
Table 3.
USP37 (ubiquitin specific peptidase 37) in the protein ubiqui-
tination pathway showed the strongest associations with nine SNPs
having p-values between 3.36610
24 and 1.94610
23 (Table 3). All
nine SNPs are in high linkage disequilibrium with each other
(r
2.0.9). The most significant SNP rs13027934 (p=3.36610
24 in
the meta-analysis) displayed a consistent association trend in each
Table 2. miRNAs differentially expressed in PBMCs of PD patients and controls.
miRNA ID
miRBase
accession
Fold-change
PD/CRTL t-statistic
1 p-value
2
Adjusted
p-value
3 B
4
miR-335 MIMAT0000765 21.78 25.26 8.78E-06 1.75E-03 3.53
miR-374a MIMAT0000727 21.97 25.24 9.21E-06 1.75E-03 3.49
miR-199a-3p/miR-199b-3p MIMAT0000232 22.18 25.04 1.66E-05 1.76E-03 2.95
miR-126* MIMAT0000444 23.02 24.94 2.26E-05 1.76E-03 2.68
miR-151-3p MIMAT0000757 21.53 24.93 2.33E-05 1.76E-03 2.65
miR-199a-5p MIMAT0000231 21.93 24.87 2.79E-05 1.76E-03 2.48
miR-151-5p MIMAT0004697 21.65 24.69 4.73E-05 2.09E-03 2.00
miR-126 MIMAT0000445 21.98 24.68 4.75E-05 2.09E-03 2.00
miR-29b MIMAT0000100 22.36 24.67 4.95E-05 2.09E-03 1.96
miR-147 MIMAT0000251 21.41 24.58 6.35E-05 2.14E-03 1.74
miR-28-5p MIMAT0000085 21.59 24.57 6.58E-05 2.14E-03 1.71
miR-30b MIMAT0000420 21.77 24.56 6.78E-05 2.14E-03 1.68
miR-374b MIMAT0004955 21.53 24.44 9.73E-05 2.53E-03 1.35
miR-19b MIMAT0000074 22.47 24.41 1.04E-04 2.53E-03 1.29
miR-30c MIMAT0000244 21.62 24.41 1.06E-04 2.53E-03 1.27
miR-29c MIMAT0000681 22.01 24.40 1.07E-04 2.53E-03 1.26
miR-301a MIMAT0000688 22.47 24.37 1.19E-04 2.65E-03 1.17
miR-26a MIMAT0000082 21.72 24.34 1.30E-04 2.75E-03 1.08
PD: Parkinson’s Disease; CTRL: Controls;
1Moderated t-statistic;
2Raw p-value;
3Adjusted p-value using the Benjamini and Hochberg method [60] or q-value;
4B-statistic or log odds that the gene is differentially expressed [16].
doi:10.1371/journal.pone.0025443.t002
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(HIHG) dataset (OR=0.57, p=0.13), in the National Institute of
Neurological Disorders and Stroke (NINDS) dataset (OR=0.46,
p=0.02), in the Center for Inherited Disease Research (CIDR)
dataset (OR=0.55, p=0.02). Consistent evidence for association
was also found for rs2059198 in ST8SIA4 (ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 4) in the glycosphingolipid
biosynthesis pathway (OR=1.20 and p=6.15610
23 in the
combined GWAS, OR=1.22 and p=0.08 in the HIHG dataset,
OR=1.17 and p=0.36 in the NINDS dataset, and OR=1.19
and p=0.05 in the CIDR dataset) (Table 3). The effect sizes of
those SNPs are small, which is expected for complex diseases: the
median odds ratio for associated SNPs in GWAS is 1.3 [28]. As a
result, none of these SNPs would survive the stringent Bonferroni
correction for multiple testing given the sample size. The trend for
association (in terms of p-values and ORs) in several GWAS
datasets and in the meta-analysis, however, supports the possible
involvement of these genes in PD etiology.
In addition, there is evidence of association with PD in the
meta-analysis for SNPs rs7315790 (p=3.55610
22) and rs10784293
(p=2.26610
22)i nUSP15 (ubiquitin specific peptidase 15),
rs10450989 (p=3.97610
22)i nUSP3 (ubiquitin specific peptidase
3), and rs878396 (p=1.04610
22), rs4149589 (p=1.96610
22), and
rs2043265 (p=2.49610
22)i nNEDD4L (neural precursor cell
expressed, developmentally down-regulated 4-like), further support-
ing the possible involvement of these pathways in PD etiology.
Figure 1. Unsupervised hierarchical clustering of the eighteen differentially expressed miRNAs (rows) for the 32 samples (columns).
The sample ID and a heat-map indicating the disease state of each subject in a color code (black for controls and red for cases) are shown at the
bottom of the plot. The color scale at the bottom right illustrates the relative expression level of a miRNA across all samples: red represents an
expression level above mean, and blue represents expression lower than the mean. The clustering is performed on log2(sample/reference pool) ratios
of the 18 differentially expressed miRNAs, using the Euclidean distance function and the average linkage clustering methods.
doi:10.1371/journal.pone.0025443.g001
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Our data identified a signature of eighteen miRNAs that
permits a good separation among PD cases and controls. All of
these 18 miRNAs are under-expressed in patients. The slight
down-regulation of these miRNAs is predicted to lead to a mild
up-regulation of their target genes. A modest over-expression of
susceptibility genes may, over time, lead to a late-onset
neurodegenerative disease such as PD [29–30].
The miR-133b, miR-433 and miR-153 miRNAs previously
implicated in PD [3–6] were not expressed at detectable levels in
the PBMCs samples assayed here, and therefore their role in PD
could not be assessed in this study. On the other hand, miR-7 was
expressed, but not deregulated in PD. Similar results for miR-133b
(not expressed) and miR-433 (not deregulated in PD) were
obtained on laser microdissected postmortem dopaminergic
neurons in a PD case-control study [29]. Discrepancies in miRNA
expression results across studies may result from technical (e.g.
sample preparation) as well as biological (e.g. tissue) differences. In
our study, we chose to focus on PBMCs not only due to the
obvious practical advantages and potential clinical applications of
these cells, but also due to important biological considerations.
Over 70% of the substantia nigra of PD patients is composed of dead
or dying cells at the time of diagnosis, and therefore expression
studies in SN tissue of PD patients is likely to reveal downstream
unspecific processes (such as programmed cell death and survival)
rather than pointing to the etiopathogenic mechanisms. Further-
more, brain-enriched miRNAs have limited stability and relatively
Table 3. Allelic association results for genes in the ‘‘miRNA-derived’’ IPA glycosphingolipid biosynthesis - ganglioseries and protein
ubiquitination pathways.
Ingenuity canonical pathway Gene symbol miRNA No. of SNPs tested SNP Chr. Location p-value
Protein ubiquitination pathway UBE4B miR-26a 21 1 NS
USP37 miR-30b, miR-30c 58 rs13006838 2 219034545 1.94E-03
rs13027934 219046825 3.36E-04
rs10498059 219050149 3.36E-04
rs7565544 219083908 4.42E-04
rs13014473 219091935 4.42E-04
rs6729124 219092735 4.42E-04
rs13022976 219093770 4.42E-04
rs6714092 219113849 6.03E-04
rs6734184 219141633 6.99E-04
UBE2F miR-30b 5 2 NS
UBE2J1 miR-30b, miR-30c 16 6 NS
UBE2H miR-335 16 7 NS
UBE2D1 miR-26a 19 10 NS
USP15 miR-26a 21 rs7315790 12 60955680 3.55E-02
rs10784293 61097595 2.26E-02
NEDD4 miR-30b, miR-30c 27 15 NS
USP3 miR-26a 9 rs10450989 15 61633561 3.97E-02
UBE2I miR-30b, miR-30c 1 16 NS
PSMD7 miR-30b 2 16 NS
UBE2G1 miR-26a 4 17 NS
USP6 miR-19b 2 17 NS
USP32 miR-19b 7 17 NS
NEDD4L miR-30b 75 rs878396 18 53962056 1.04E-02
rs4149589 53966015 1.96E-02
rs2043265 54206752 2.49E-02
USP25 miR-26a 6 21 NS
Glycosphingolipid biosynthesis -
ganglioseries
DBT miR-29b, miR-29c 5 1 NS
ST3GAL5 miR-19b 5 2 NS
ST8SIA4 miR-30b 85 rs2548278 5 100193016 3.39E-02
rs2059198 100232402 6.15E-03
rs17160771 100238725 3.61E-02
ST8SIA3 miR-301a 4 18 NS
P-values for significantly associated polymorphisms in the HIHG, CIDR and NINDS meta-dataset are shown.
NS: None significant.
doi:10.1371/journal.pone.0025443.t003
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short post-mortem brain freezing intervals (,1 h) [31]. There is
communication between the brain and immune system through
multiple mechanisms that may be reflected in blood cells [32], and
PBMCs share more than 80% of the transcriptome with other
tissues types including brain [33]. Finally, previous expression
profiling studies for neurodegenerative diseases in PBMCs have
uncovered important and novel findings [34], and the miRNA
expression pattern in normal brain appears to be more similar to
PBMCs than to other tissues [35].
The mis-classification of several individuals in HC and PCA
analyses could not be correlated to any experimental artefact or
error (such as collection date or sample switching), nor to any
study participant characteristic (such as age, sex, medication).
Even though mis-clustering of individuals is characteristic of high-
throughput methods [36], it might have been resolved by the
inclusion in the expression study of samples from patients with
other parkinsonian syndromes with involvement of the SN such as
progressive supranuclear palsy, frontotemporal dementia with
parkinsonism [37], and corticobasal degeneration.Consistent with
the view that idiopathic PD most likely requires multiple insults in
different biological processes before neuronal loss occurs [38], our
‘‘miRNA-derived IPA analysis’’ revealed that several of the top
canonical pathways over-represented among our target genes have
been previously linked to PD. This is the case for pathways such as
the semaphorin signaling in neurons and the DNA methylation
and transcriptional repression signaling. Semaphorins are axon
guidance proteins playing important roles in the mesencephalic
dopamine neuron system development during embryogenesis. A
GWAS showed that a SNP in SEMA5A was the most significantly
associated with PD [8]. However, four subsequent case-control
replication studies reported contradictory results [39–42]. DNA
methylation and transcriptional repression signalling was the third
most significantly over-represented pathway. Mechanisms regu-
lating gene expression, whether through DNA methylation or
signalling pathways such as checkpoint transduction cascades or
transcriptional repression, are very likely associated to PD and
regulated by miRNAs. Saijo et al. demonstrated that Nurr1/
CoREST transrepression pathway attenuates neurotoxic inflam-
mation, protecting against loss of dopaminergic neurons in PD
[43]. Also, Zhong et al. presented DJ-1 as a potential regulator of
protein sumoylation and directly link the loss of DJ-1 expression
and transcriptional dysfunction to impaired dopamine synthesis
[44].
Genetic and biochemical studies have established a central role
for a-synuclein accumulation in the pathogenesis of Parkinson
disease. In this study, we identified a large set of putative a-
synuclein target (interacting) genes in human H4 neuroglioma
cells, which we extensively use as a model for studying the
molecular basis of PD [45–46], providing the first insight into the
interacton of endogenous a-synuclein. Pathway analysis of this
interacton suggested several primary targets of a-synuclein, with
the glycosphingolipid biosynthesis and the protein ubiquitination
pathways being common to the miRNome IPA analysis. Data
mining of these pathways in three GWAS studies highlighted the
consistent associations of USP37 and ST8SIA4 with PD and gave
further support to the involvement of glycosphingolipids and the
ubiquitin proteasome system in the physiopathology of PD.
Furthermore, 3 miRNAs (miR-30b, miR-30c and miR-26a) which
are among the most abundant miRNAs in primary human
neuronal and glial cells [31] and simultaneously involved in the
regulation of a-synuclein interacting genes, emerged as the main
modulators of these two pathways in our expression analyses.Gly-
cosphingolipids and their sialic acid-containing derivatives,
gangliosides, are important cellular components and abundant in
the nervous system. They are known to undergo dramatic changes
during brain development, but our knowledge on the mechanisms
underlying their quantitative and qualitative changes is still
fragmentary [47]. Glycosphingolipids are closely related to the
ceramide metabolism that has already been linked to PD through
the glucocerebrosidase (GBA) gene [26–27].
In addition to being the major non-lysosymal system for
degrading proteins in the cell, the ubiquitin proteasome system
(UPS) regulates function and translocation of proteins, many of
which play a rolein the determination of cell fate. Proteinmediators
of apoptosis are regulated by the UPS, via direct or indirect
modulation of proteins associated with cell death. Mutations in two
PD genes, the E3-ligase Parkin and the deubiquitinating enzyme
UCHL1, may lead to a susceptibility to UPS failure resulting in
protein accumulation, Lewy body formation and dopaminergic cell
death. Furthermore, dysfunctional a-synuclein and a-synuclein
oligomeric species have also been implicated in the impairment of
the proteasome system [48], which in turn has been implicated in
a-synuclein turnover [15]. Several ubiquitin specific proteases
(e.g. USP24 and USP40) have been consistently associated with PD
[49–52].
To our knowledge, this is the first global miRNAs expression
analysis performed in PBMCs in a relatively large cohort of PD
patients and controls. Taken together, this work suggests that a
small subset of miRNAs may act as regulators of cellular
mechanisms leading to PD. Some of the pathways highlighted
here are already known to be involved in PD pathogenesis, but
others constitute new avenues for future research.
Materials and Methods
Ethics Statement
The Lisbon University Hospital’s ethical committee approved
the study, and all participants or their legal representatives signed
an informed consent.
Patient and control samples
Study participants were recruited at the movement disorders
outpatient clinic of the Lisbon University Hospital over a period of
eight months. Patients were evaluated by neurologists with
expertise in PD. Diagnosis of Parkinson’s disease was based on
the UK Parkinson’s Disease Society Brain Bank’s criteria [53]. All
recruited patients had more than two years of disease duration,
therefore significantly reducing the probability of including
atypical or secondary causes of parkinsonism [53]. Controls demon-
strated no signs of parkinsonism and had no family history of PD.
Patients’ clinical assessment included the modified Hoehn and Yahr
staging [54], the Schwab and England Activities of Daily Living
Scale [55], and the Unified Parkinson’s Disease Rating Scale
(UPDRS) [56]. All participants were Portuguese Caucasians.
Sample collection and RNA isolation
Approximately 16 ml of whole blood was collected per
participant by venipuncture into two BD Vacutainer CPT glass
tubes (Becton-Dickinson). Within two hours of blood collection,
PBMCs were isolated from the CPT tubes by centrifugation
(30 minutes, 1639 g, room temperature), washed twice with PBS
(15 minutes, 353 g,4 uC) and conserved on RNA later (Qiagen).
Total RNA containing small RNAs species was extracted from
PBMCs using the miRNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions, aliquoted and stored at 280uC. Since
high-quality RNA is an absolute prerequisite to obtain reliable and
reproducible microarray data, all samples passed an extensive
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Nanodrop ND1000 and RNA Integrity Number.7 in the Agilent
2100 Bioanalyser).
miRNA profiling
RNA samples were sent to Exiqon (Denmark) for miRNA
profiling. Briefly, 1 mg of total RNA from samples meeting the
quality standards described above were labeled with the miRCUR-
Y
TM Hy3
TM/Hy5
TM power labeling kit and hybridized on the
miRCURY
TM locked nucleic acid (LNA) array (version 10.0) using
a Tecan HS4800 hybridization station. Each sample was co-
hybridizedwitha Hy5-labeled commonreferencepool composed of
equal RNA concentrationof the 39 samples(the 32 under study and
7 additional samples, later excluded from differential expression
analysisduetoarrayqualitycontrolproblems).Arrayswerescanned
with an Agilent G2565BA Microarray Scanner System and stored
in an ozone-free environment in order to prevent potential
bleaching of the fluorescent dyes. Image analysis was carried out
using the ImaGene 7.0 software (BioDiscovery) and the resulting
ImaGene output files were analyzed using the Limma package [16]
implemented in the R freeware (http://cran.r-project.org/). Micro-
array data submission for human arrays is MIAME compliant. Raw
data from the microarray study have been deposited in the Gene
Expression Omnibus (GEO) database with the accession number
GSE16658. Background correction was performed using the
normexp method (with offset=10). Intensities of good quality spots
were then subjected to within-array (loess method) normalization.
Intensities lower than 1.5 times the median signal intensity of the
respective slide and labelwerediscarded.The‘‘calling’’ofa miRNA
on a particular array fails if two or more of the four replicated
capture probes for this miRNA are flagged as bad quality spots by
the image analysis software. Differential miRNA expression
between controls and PD patients was assessed using linear
regression analysis and empirical Bayes methods implemented in
the Limma package.
Hierarchical clustering and principal component analysis of the
samples were performed with the Partek Genomics Suite software
v.6.5 using the log2(sample/reference) ratios of the 18 differentially
expressed miRNAs as input. HC was performed using the
Euclidean distance function and the average linkage clustering
methods. PCA analysis was set to run using the following options:
covariance dispersion matrix (used when the variables are measured
in the same units and have similar variances) and normalized
eigenvector scaling (orthogonal eigenvectors and scaled to unit).
Chromatin immunoprecipitation followed by sequencing
analysis
Human H4 neuroglioma cells (HTB-148-ATCC, Manassas)
were maintained in OPTI-MEM (Life Technologies) supplement-
ed with 10% fetal bovine serum and maintained at 5% CO2,3 7 uC
to confluence. The cells were cross-linked in 1% formaldehyde for
10 minutes at room temperature and pelleted by low-speed
centrifugation (1000 g). The cells were then lysed in lysis buffer
(1.0% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1) containing
Protease Inhibitor Cocktail (Roche). Chromatin was sheared to an
average DNA fragment size of 100–500 bp by sonication using the
Diagenode Bioruptor sonicator (2615 minutes of 30-second bursts
at high output power with 30-second rest intervals between pulses)
and fragment sizes were checked by agarose gel electrophoresis
and with the Agilent Bioanalyzer DNA 1000 kit. 100 mlo f
chromatin was aliquoted as total input (Input) and immunopre-
cipitated (IP) for later steps. Chromatin was precleared with 45 ml
Protein G-Agarose solution (Upstate), followed by the immuno-
precipitation using 2.5 mgo fa-synuclein antibody (Ref. No. 610786,
BD Biosciences) overnight at 4uC with slow rotation. Subsequently,
the beads were washed using Buffer 1 (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 100 mM NaCl),
Buffer 2 (Buffer 1 with 500 mM NaCl), Buffer 3 (0.25 M LiCl, 1%
NP-40, 1% C24H39NaO4, 1 mM EDTA, 10 mM Tris-HCl), and
26TE Buffer. Chromatin was eluted by vortexing and rotation at
room temperature in 1% SDS and 0.1 M NaHCO3. To reverse the
crosslinks, precipitated chromatin was incubated at 65uC overnight
by adding NaCl (to 0.2 M) and then phenol-extracted. The DNA
was purified using the QIAquick PCR Purification Kit (Qiagen).
The total amount of DNA was measured using PicoGreen
(Invitrogen) and a NanoDrop Spectrophotometer. Immunoprecip-
itated DNA and total input DNA were blunt ended and adapters
were ligated to the ends, according to the library preparation
protocol from Illumina. The DNA fragments with 200625 bp in
length were then selected for the construction of the ChIP-seq DNA
library. The quality of the libraries was checked using the Agilent
Bioanalyzer HS DNA Kit, showing correct size and concentration
of the samples. Following the size selection, all the resulting
immunoprecipitated DNAfragmentswereamplifiedand sequenced
simultaneously using the Illumina Genome Analyzer II.
Using the ELAND software (Illumina), 9.694.993 reads were
aligned to the repeat masked NCBI 36/hg18 build of the human
genome, allowing up to two mismatches. The Partek Genomics
Suite (Partek) ChIP-seq analysis workflow was utilized to identify
a-synuclein enriched regions. The software uses a sliding window
approach to identify regions of higher read depth, referred to as
peaks, relative to a background distribution. We used a 100 bp
window and the zero-truncated binomial model with a peak cut-
off p-value of 0.001.
Validation of ChIP-seq results by ChIP real-time PCR
The original IP and Input DNA aliquots from the microarray
experiment were used to assess the quality of the ChIP. a-
synuclein occupancy was detected by qPCR at the CDC-42 and
NEDD4 promoters. Primers were designed with the PRIMER3
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3-www.
cgi). The primer sequences were as follows: CDC-42 forward
GATGCACCACTGTTCTCCAG, reverse AGACACCTCTC-
CTCCTTCCAC; NEDD4 forward GTAACGAGCCCTTCCT-
GTGA, reverse TCAACTACCCGACCGACTTC; myoglobin
exon 2 forward AAGTTTGACAAGTTCAAGCACCTG, reverse
TGGCACCATGCTTCTTTAAGTC. The qPCR was performed
on a Roche LightCycler in triplicate. The quality of the ChIP was
calculated as fold enrichment over myoglobin exon 2 non-binding
control region.
Pathway analyses
Predicted target genes or the a-synuclein interacting genes were
uploaded into the commercially available IPA software v.7.6 for
biological function and pathway analysis. IPA is built upon a very
large manually-curated and up-to-date database of genes, proteins,
functions, interactions/networks, and pathways. The IPA ‘‘Core
Analysis’’ was performed using the Ingenuity Knowledge Base
(IPAKB, Genes only) as the reference set, using direct and indirect
relationships for network analysis, and data from mammal species,
and all tissues, cell lines and data sources. The significance (p-
values) of the association between a dataset and a canonical
pathway was determined by comparing the number of genes in a
dataset that participate in a given pathway to the total number of
occurrences of these genes in all pathway annotations that are
stored in the IPAKB. A Fisher’s exact test was used to calculate the
p-value to determine the probability that the association between
the genes in the dataset and the canonical pathway is explained
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p,0.05. Each pathway analysis generated the top canonical
pathways with a statistical significance (Figures S4A and S4B).
Whole-genome association data mining
A joint association analysis was performed on three PD GWAS
datasets: The HIHG at the University of Miami [13], the NINDS
[9], and the joint dataset from the Progeni/GenePD studies that
was genotyped at the CIDR [10]. This meta-dataset has a
combined sample size of 1752 cases and 1745 controls. Details
regarding the characteristics of the study participants and the
markers analyzed in each dataset are described in detail in the
original reports [9,10,13]. Briefly, genotype and phenotype data
from the NINDS and Progeni/GenePD studies were downloaded
from dbGAP (http://www.ncbi.nlm.nih.gov/sites/entrez?db=-
gap). HIHG genotype data were generated using the Illumina
Infinium 610-quad BeadChip. Imputation of SNP genotypes from
the three GWAS dataset was performed using the software
package Impute [57]. Samples with a genotyping efficiency ,0.98
and SNPs with a genotyping call rate ,0.98 were removed from
the analysis. In addition, SNPs with a minor allele frequency
,0.01 or a Hardy-Weinberg equilibrium p-value,10
27 (in
controls) were excluded. Population stratification was evaluated
using Eigenstrat [58]. Cochran-Armitage trend tests were used to
assess allelic association at each SNP using PLINK [59].
Supporting Information
Figure S1 Validation of microarray expression results
by qRT-PCR of five miRNAs. Five miRNAs showing
distinctive expression patterns between PD and control samples
were selected for global validation of the microarray results by
qRT-PCR on the same dataset of 19 PD cases and 13 controls. We
selected miRNAs (miR-126*, miR-32 and miR-101) that were
under-expressed (fold-change ,21), and miRNAs (miR-15b and
miR-550) that were over-expressed (fold-change.1) in the micro-
arrays, both above (miR-126*) and below (miR-32, miR-101, miR-
15b, and miR-550) our threshold for significance (B-statistic$1).
Normalization to endogenous expression levels of control genes is
currently the most accurate method to correct for potential RNA
input or RT efficiency biases. The NormFinder algorithm [61] was
used to assess the variance in expression levels in our miRNAs and
to select the best candidate endogenous controls (three small
nuclear/nucleolar RNAs RNU66, RNU6B and Z30, and miRNA
miR-103) for qPCR normalization. Quantification of selected
miRNAs and endogenous controls by TaqManH Real-Time PCR
was carried out as described by the manufacturer (Applied
Biosystems [ABI]). Briefly, 50 ng of template RNA was reverse
transcribed using the TaqManH MicroRNA Reverse Transcription
Kit and stem-loop miRNA-specific primers from the ABI assays
(TaqManH MiRNA assays miR-126*, miR-32, miR-101, miR-15b,
miR-550, miR-103, RNU66, RNU6B and Z30). 1.33 ml of each
RT product was PCR-amplified in triplicate in 20 ml PCR reactions
(95uC for 10 minutes, followed by 50 cycles of 95uC for 15 seconds
and 60uC for 1 minute) in 384-well plates on the ABI 7900HT Fast
Real-TimePCRSystem (ABI).Foreachassay,a pairedno-template
control (NTC) and a common reference pool (equal quantity of
RNA from the 19 cases and 13 controls) reactions were performed.
Based on the qRT-PCR results, miR-103 was selected by
NormFinder as the best endogenous control (stability value of
0.223) and was further used as the reference miRNA to normalize
expression levels.Expressionvalueswere calculatedusingtheDDCT
method: 2
2(DC
T
[sample]2DC
T
[pool]) with DCT=C T(selected miR-
NA)2CT(miR-103) [62].ThePD/control expressionratio(expected
valuebetween0and+‘)iscalculated bydividingthe average DDCT
of cases by the average DDCT of controls. Ratio values between 0
and 1 indicate that a miRNA is down-regulated in PD patients, and
values greater than 1 mean that it is up-regulated in PD patients.
Ratiovaluescanbeconvertedtothemoreintuitivefold-change(FC)
values by taking the negative inverse (21/ratio) for ratios between 0
and 1 (e.g. a ratio of 0.5 corresponds to a 22 FC, which means that
the miRNA is 2-fold down-regulated in cases). FC values are equal
to ratios for ratios greater than one. The expected values of FC
are ]2‘ ;21] and [1;+‘[. A two-tailed t-test with unequal variance
was used to assess significant differences in qRT-PCR among cases
and controls. The table below the graph indicates the fold-changes
and B-statistics obtained for the selected miRNAs in the microarray
experiment, as well as the fold-changes and p-values obtained in the
qRT-PCR experiment.
(PDF)
Figure S2 Two-dimensional principal component anal-
ysis (PCA) plot of the 32 individuals. PCA analysis was based
on the expression levels of the eighteen differentially expressed
miRNAs. Control and patient samples are shown in black and red,
respectively. Males are represented by squares and females by
circles, and the individual’s ID (Table 1) is indicated inside the
symbol.
(PDF)
Figure S3 Sources of variation in the miRNomics
expression data. Analysis of variance (3-way ANOVA) was
used to evaluate the impact of several potential sources of variation
(age, gender and affection status) in our expression data.
(PDF)
Figure S4 Top ten canonical pathways over-represented
among the predicted target genes of 11 out of the 18
differentially expressed miRNAs (A) and among the 238
genes targeted by a-synuclein (B). These analyses were
carried out using the Ingenuity Pathway Analysis software and
each plot displays the pathways ranked by significance level on the
y-axis. The x-axis on the top is for the negative logarithm of the p-
value (orange dots connected by a line). The significance (p-values)
of the association between a dataset and a canonical pathway was
determined by comparing the number of genes in a dataset that
participate in a given pathway to the total number of occurrences
of these genes in all pathway annotations that are stored in the
Ingenuity Knowledge Base. The p-value is calculated using the
right-tailed Fisher exact test to determine the probability that the
association between the genes in the dataset and the canonical
pathway is explained only by chance. The number of genes in our
dataset in a given pathway and the total number of genes
associated with that pathway in the IPA’s database are shown to
the right of each pathway and are used to calculate the percentage
displayed in the grey bars (the x-axis on the bottom is for the grey
bars). The percentage and the significance are measures of the
amount and confidence, respectively, of association of a given
canonical pathway with the data.
(PDF)
Table S1 959 target genes (662 unique genes) predicted by
miRecords for 11 differentially expressed miRNAs. Only genes
that are predicted to be targets by at least six softwares are shown.
(XLS)
Table S2 Top ten canonical pathways in the Ingenuity Pathway
Analysis of the 662 genes predicted to be targets of 11 differentially
expressed miRNAs. The target genes and their respective miRNA
in each pathway are indicated. The ratio corresponds to the
number of genes in a pathway that were in our target gene list
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is calculated using the right-tailed Fisher exact test and takes into
account the number of genes in our dataset in a given pathway
and the total number of genes associated with that function in
IPA’s database. The ratio and the significance are measures of the
amount and confidence, respectively, of association of a given
canonical pathway with the data.
(XLS)
Table S3 ChIP-seq target genes containing the a-synuclein
enriched regions overlapping with the transcribed sequences.
(XLS)
Table S4 Allelic association results for SNPs in the glycosphin-
golipid biosynthesis - ganglioseries and the protein ubiquitination
pathway target genes.
(XLS)
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